Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent vs Sequential Erlotinib and Chemotherapy in EGFR-Mutant NSCLC
NCT02886195Phase 3Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of erlotinib, pemetrexed, cisplatin in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
erlotinibpemetrexedcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02886195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886195.